Leukemia inhibitory factor promotes human cholangiopathies, and its inhibition improves cholestasis in Abcb4 −/− mice

20250 citationsJournal Articlegold Open Access

Authors

Cristina Di Giorgio · University of Perugia

Ginevra Urbani · University of Perugia

Carmen Massa · University of Perugia

Silvia Marchianò · University of Perugia

Michele Biagioli · University of Perugia

Martina Bordoni · Centro Ricerche Produzioni Animali

Ginevra Lachi ·

Abstract

Cholangiocyte-derived LIF promotes the formation of a pro-inflammatory and pro-fibrotic niche centred on damaged cholangiocytes. LIFR antagonism reverses fibrosis and immune dysregulation in Abcb4-/- mice, supporting the development of anti-LIFR therapies in human cholangiopathies.

Topics & Keywords

Liver Diseases and Immunity Liver Disease Diagnosis and Treatment Pediatric Hepatobiliary Diseases and Treatments

Publication Details

Published in: Hepatology Communications

Volume 9, Issue 9

DOI: 10.1097/hc9.0000000000000779

Field-Weighted Citation Impact: 0.00

Command Palette

Leukemia inhibitory factor promotes human cholangiopathies, and its inhibition improves cholestasis in Abcb4 −/− mice

Authors

Abstract

Topics & Keywords

Publication Details